Login to Your Account



Clavis Shares Boosted on Elacytarabine Data in AML

By Cormac Sheridan
Staff Writer

Monday, December 10, 2012
The numbers may be too small to allow any firm conclusions to be drawn, but Clavis Pharma ASA reported positive Phase II data for a combination of elacytarabine and idarubicin in patients with early stage acute myeloid leukemia (AML) who had either relapsed on or proved refractory to a first-line therapy that included cytarabine.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription